Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices

NCT03502811 · View on ClinicalTrials.gov ↗

Study Summary

The MitraClip EXPAND Study (A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip Devices) is designed to confirm the safety and performance of the MitraClip NTR System and MitraClip XTR System.

Interventions

  • DEVICE MitraClip NTR/XTR System

Study Locations (20)

California

  • Scripps Health — La Jolla
  • Cedars-Sinai Medical Center — Los Angeles
  • University of California - Davis Medical Center — Sacramento

New York

  • New York-Presbyterian/Columbia University Medical Center — New York
  • Mount Sinai Hospital — New York
  • New York University Hospital — New York

Alabama

  • Baptist Medical Center Princeton — Birmingham

Arizona

  • Phoenix Cardiovascular Research Group — Phoenix

Colorado

  • University of Colorado Hospital — Aurora

Florida

  • JFK Medical Center — West Palm Beach

Illinois

  • Northwestern Memorial Hospital — Chicago

Kansas

  • Via Christi Regional Medical Center - St. Francis Campus — Kansas City

Trial Details

FieldValue
Enrollment Target 1,041 participants
Start Date 2018-04-26
Est. Completion 2020-12-31

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03502811

The ClinicalTrials.gov registry entry for NCT03502811 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,041 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention — of which MitraClip NTR/XTR System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03502811 reports 20 study locations spanning 16 distinct geographic areas — top geographies include California, New York, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03502811 about?

NCT03502811 is a clinical study titled "The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices". The MitraClip EXPAND Study (A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip Devices) is designed to confirm the safety and performance of the MitraClip NTR System and MitraClip XTR System.

What is the current status of trial NCT03502811?

This trial is currently completed. The enrollment target is 1,041 participants. The study started on 2018-04-26. Estimated completion is 2020-12-31.

What conditions does trial NCT03502811 study?

This clinical trial studies the following conditions: Mitral Regurgitation, Mitral Valve Regurgitation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03502811?

The interventions under investigation include: MitraClip NTR/XTR System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03502811?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03502811 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial